CCI-779 and Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney Cancer

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00112840
First received: June 2, 2005
Last updated: September 4, 2014
Last verified: January 2014
  Purpose

This phase I/II trial is studying the side effects and best dose of CCI-779 and bevacizumab and to see how well they work in treating patients with metastatic or unresectable kidney cancer. Drugs used in chemotherapy, such as CCI-779, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some find tumor cells and kill them or carry tumor-killing substances to them. Others interfere with the ability of tumor cells to grow and spread. Bevacizumab may also stop the growth of kidney cancer by blocking blood flow to the tumor. Giving CCI-779 together with bevacizumab may kill more tumor cells.


Condition Intervention Phase
Clear Cell Renal Cell Carcinoma
Recurrent Renal Cell Cancer
Stage IV Renal Cell Cancer
Drug: CCI-779
Drug: Bevacizumab
Phase 1
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I/II Trial of CCI-779 and Bevacizumab in Stage IV Renal Cell Carcinoma

Resource links provided by NLM:


Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Dose-limiting Toxicity (DLT) (Phase I) [ Time Frame: Patients observed a minimum of 4 weeks (one full course). The maximum number of cycles observed was 16 cycles. ] [ Designated as safety issue: Yes ]

    For this protocol, dose limiting toxicity (DLT) will be defined as an adverse event attributed (definitely, probably, or possibly) to the study treatment in the first four weeks of combination therapy, and meeting the following criteria:

    • Grade 4 Absolute neutrophil count (ANC) for 5+ days.
    • Grade 4 anemia or thrombocytopenia of any duration.
    • Serum Creatinine 2 times baseline or 2x upper limit of normal if baseline levels not normal.
    • Any other non-hematologic grade 3 or higher as per NCI Common Terminology Criteria for Adverse Events (CTCAE) v. 3.0, except fatigue and grade 3 Hypertension that is will be controlled with oral medication.
    • Grade 3 triglycerides will be a DLT for patients who have Grade 3 in spite of appropriate lipid lowering drug therapy.

    The maximum tolerated dose level (MTD) will be defined as the highest safely tolerated dose where 1 or 0 out of 6 patients experience DLT with the next higher dose.


  • Proportion of Progression-free Patients at 6 Months (Phase II) [ Time Frame: 6 months after study entry ] [ Designated as safety issue: No ]
    Determination of progression will be made according to Response Evaluation Criteria in Solid Tumors (RECIST). A progression (PD) is defined as having at least a 20% increase in the sum of the longest dimension of target lesions taking as reference the smallest sum of the largest dimension recorded at baseline.The proportion of progression-free patients will be estimated by the number of successes divided by the total number of evaluable patients. Ninety-five percent confidence intervals for the success proportion will be calculated. All patients meeting the eligibility criteria who have signed a consent form and begun treatment will be considered evaluable. Those who die will be considered to have had disease progression unless documented evidence clearly indicates no progression has occurred.


Secondary Outcome Measures:
  • Clinical Best Response Rate of CCI-779 and Bevacizumab in Patients With Metastatic Renal Cell (Phase II) [ Time Frame: Up to 3 years from study registration ] [ Designated as safety issue: No ]

    The number of participants with clinical tumor response to treatment will be evaluated using the Response Evaluation Criteria In Solid Tumors (RECIST).

    >>

    >> Complete Response (CR): Disappearance of all target lesions

    >>

    >> Partial Response (PR): At least a 30% decrease in the sum of the largest dimension (LD) of target lesions taking as reference the baseline sum LD.


  • Time to Progression (Phase II) [ Time Frame: Up to 3 years from study registration ] [ Designated as safety issue: No ]
    The time to progression is defined as the time from registration to the time of progression. Those who die will be considered to have had disease progression unless documented evidence clearly indicates no progression has occurred. The distribution of time to progression will be estimated using the method of Kaplan-Meier.

  • Overall Survival (Phase I and II) [ Time Frame: Up to 3 years from study registration ] [ Designated as safety issue: No ]
    The overall survival or survival time is defined as the time from registration to death due to any cause. The distribution of overall survival will be estimated using the method of Kaplan-Meier.

  • Time to Treatment Failure (Phase I and II) [ Time Frame: Up to 3 years from study registration ] [ Designated as safety issue: No ]
    Time to treatment failure is defined as the time from study entry to the date patients end treatment. Time to treatment failure will be evaluated using the method of Kaplan-Meier.


Enrollment: 60
Study Start Date: May 2005
Estimated Study Completion Date: December 2014
Primary Completion Date: August 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: CCI-779 and bevacizumab
Patients receive CCI-779 IV on days 1, 8, 15, and 22 and bevacizumab IV on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of CCI-779 and bevacizumab until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Phase II patients receive CCI-779 and bevacizumab as in phase I at the MTD determined in phase I. After completion of study treatment, patients are followed every 3 months until disease progression and then every 6 months for up to 3 years after study entry.
Drug: CCI-779
CCI-779 is taken IV on days 1, 8, 15, 22 of a 28-day cycle. Dose level is dependent on phase.
Other Names:
  • Temsirolimus
  • Torisel Rapamycin analog
  • WAY-130779
Drug: Bevacizumab
Bevacizumab is taken IV on Days 1 and 15 of a 28-day cycle. Dose Level determined by phase.

Detailed Description:

PRIMARY OBJECTIVES:

I. To determine the maximally tolerated dose (MTD) and recommended dosing for the combination of CCI-779 and Bevacizumab in patients with metastatic renal cell cancer. (Phase I) II. To determine the proportion of patients with metastatic renal cell cancer who are progression free at 6 months. (Phase II)

SECONDARY OBJECTIVES:

I. To determine the toxicity of the combination of CCI 779 and Bevacizumab in patients with metastatic renal cell cancer. (Phase II) II. To determine the clinical response rate of CCI 779 and Bevacizumab in patients with metastatic renal cell cancer. (Phase II) III. To determine the time to progression (TTP), disease free survival, and overall survival of CCI 779 and Bevacizumab in patients with metastatic renal cell cancer. (Phase II)

TERTIARY OBJECTIVES:

I. To identify predictive molecular markers of response, both at the tumor level and in the plasma/serum level, in an exploratory manner.

II. To correlate blood markers of angiogenesis with clinical activity of the combination of CCI-779 and Bevacizumab.

OUTLINE: This is a multicenter, phase I dose-escalation study followed by a phase II study. Patients are stratified according to study phase (I vs II).

Phase I: Patients receive CCI-779 IV on days 1, 8, 15, and 22 and bevacizumab IV on days 1 and 15.

Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of CCI-779 and bevacizumab until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Phase II: Patients receive CCI-779 and bevacizumab as in phase I at the MTD determined in phase I. After completion of study treatment, patients are followed every 3 months until disease progression and then every 6 months for up to 3 years after study entry.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically confirmed metastatic or unresectable renal cell cancer

    • Must have a component of conventional clear cell histology
    • The following histologies are excluded:

      • True papillary
      • Sarcomatoid features without any clear cell component
      • Chromophobe
      • Oncocytoma
      • Collecting duct tumors
      • Transitional cell carcinoma
  • Measurable disease, defined as ≥ 1 lesion ≥ 2.0 cm in the longest diameter by conventional techniques OR ≥ 1.0 cm by spiral CT scan
  • Tumor tissue (from primary tumor or metastases) available AND patient is willing to donate blood for research studies (phase II only)
  • No CNS metastases by head CT scan or MRI
  • Performance status - ECOG 0-2
  • Absolute neutrophil count ≥ 1,500/mm^3
  • Platelet count ≥ 100,000/mm^3
  • Hemoglobin ≥ 9.0 g/dL
  • No evidence of bleeding diathesis or coagulopathy
  • No history of clinically significant bleeding or active bleeding
  • Bilirubin ≤ 1.5 times upper limit of normal (ULN)
  • Alkaline phosphatase ≤ 2.5 times ULN (5 times ULN if liver metastases are present)
  • AST ≤ 2.5 times ULN (5 times ULN if liver metastases are present)
  • PT/INR ≤ 1.5

    • Patients on full-dose warfarin or stable-dose low molecular weight heparin must have INR > 1.5 but ≤ 3
  • Creatinine ≤ 1.5 times ULN
  • Urine protein ≤ 1+ by dipstick or urinalysis
  • Urine protein < 1,000 mg on a 24-hour urine collection
  • No cerebrovascular accident within the past 6 months
  • No peripheral vascular disease with claudication on < 1 block
  • No New York Heart Association class II-IV congestive heart failure
  • No angina pectoris requiring nitrate therapy
  • No myocardial infarction within the past 6 months
  • No uncontrolled hypertension, defined as systolic blood pressure (BP) ≥ 160 mm Hg and/or diastolic BP ≥ 90 mm Hg despite medication
  • No cardiac arrhythmias
  • No other significant cardiovascular disease
  • No ongoing hemoptysis
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception during and for at least 3-4 months after study participation
  • Fasting cholesterol ≤ 350 mg/dL
  • Triglycerides ≤ 1.5 times ULN (may achieve using lipid lowering agents)
  • No known hypersensitivity to recombinant human antibodies
  • No significant traumatic injury within the past 4 weeks
  • No serious or non-healing wound, ulcer, or bone fracture
  • No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 4 weeks
  • No pathological conditions that confer a high risk of bleeding (e.g., tumor involving major vessels or known varices)
  • No diabetes
  • No other currently active malignancy except nonmelanoma skin cancer

    • Patients are not considered to have a currently active malignancy if they have completed anticancer therapy AND are considered to be at < 30% risk of relapse
  • No other uncontrolled serious medical or psychiatric condition
  • At least 4 weeks since prior biologic response modifiers for metastatic disease
  • No prior bevacizumab or mTOR inhibitors
  • At least 4 weeks since prior chemotherapy for metastatic disease
  • Prior palliative radiotherapy to metastatic lesions allowed provided there is ≥ 1 measurable and/or evaluable lesion that has not been irradiated
  • At least 4 weeks since prior and no concurrent radiotherapy
  • Prior nephrectomy allowed
  • More than 4 weeks since prior major surgery or open biopsy
  • More than 1 week since prior core biopsy
  • No concurrent major surgery
  • At least 4 weeks (2 weeks for vascular endothelial growth factor [VEGF] receptor tyrosine kinase inhibitor [RTKI] therapy) since prior and no more than 2 therapies (phase II)

    • One of these therapies must have included a RTKI agent administered for a minimum of 4 weeks
  • Concurrent full-dose warfarin or low molecular weight heparin allowed provided dose is stable AND INR requirements are met
  • Concurrent zoledronate for bone metastases and/or hypercalcemia allowed provided therapy was initiated prior to study entry
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00112840

Locations
United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
United States, Wisconsin
University of Wisconsin Hospital and Clinics
Madison, Wisconsin, United States, 53792
Sponsors and Collaborators
Investigators
Principal Investigator: Jaime Merchan Mayo Clinic
  More Information

No publications provided

Responsible Party: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT00112840     History of Changes
Other Study ID Numbers: NCI-2009-00109, NCI-2009-00109, CDR0000428311, NCI-6986, MC0452, 6986, N01CM62205
Study First Received: June 2, 2005
Results First Received: January 6, 2014
Last Updated: September 4, 2014
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Carcinoma
Carcinoma, Renal Cell
Adenocarcinoma
Kidney Diseases
Kidney Neoplasms
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Urogenital Neoplasms
Urologic Diseases
Urologic Neoplasms
Bevacizumab
Everolimus
Sirolimus
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antifungal Agents
Antineoplastic Agents
Growth Inhibitors
Growth Substances
Immunologic Factors
Immunosuppressive Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses

ClinicalTrials.gov processed this record on October 23, 2014